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Prefractionated library: a generic term that is typically used to describe any fractionation of crude extracts before primary screening. Prefractionation of crude extracts into fractions containing a few to many components is achieved by column chromatography, high-performance liquid chromatography (HPLC), or liquid-liquid partitioning. The simplest prefractionation protocols can reduce a crude extract to one fraction (e.g. the enrichment of alkaloids in a sample using cation exchange) while more involved procedures have been reported to afford up to 200 fractions per crude extract.
Mass-directed isolation: the process of isolating compounds from some type of biota (e.g., marine invertebrates, plants, microbes, etc.) that is based solely on mass spectrometric (MS) data. In relation to biodiscovery, this involves the initial identification of MS ions in a bioactive extract or fraction that is predicted to correspond to the active compound(s). Compounds are isolated following large-scale extraction of biota by chromatography and MS analysis of the fractions. Biological evaluation is then undertaken to confirm activity and potency.
Bioassay-guided fractionation: the process of isolating biologically active compounds from some type of biota (e.g. marine invertebrates, plants, microbes, etc.) that is based solely on bioactivity. Biological screening initially identifies a bioactive extract or fraction from a NP-based library. Large-scale extraction of the relevant biota is then undertaken, followed by iterative rounds of chromatography withd biological testing conducted after each fractionation step. Only those fractions showing bioactivity undergo subsequent separation, and this is a process requiring many cycles until the compound(s) responsible for initial screening activity are isolated. Dereplication: the process by which the chemical and biological characteristics of the unknown compounds are compared with the chemical and biological characteristics of known compounds from databases to eliminate those that have been identified previously. Some NPs are discovered more frequently than others during screening programs. As the number of described NPs increases, so does the probability of rediscovering known compounds. About 34% of current marketed drugs can trace their origins back to an unmodified natural product (NP) or a semi-synthetic analogue [6] . While this metric reflects the historic role NPs have played in the pharmaceutical industry, it does not capture the reality that this once popular approach has waned considerably since the early 1980s. The decline can be traced back to a paradigm shift that coalesced advances in molecular biology, combinatorial chemistry and high-throughput screening (HTS). It was expected that combinatorial chemistry would deliver massive numbers of novel chemical motifs that would ultimately result in the filing of increasing numbers of new chemical entities (NCEs) . At the same time biodiverse collections became harder to legally acquire and use for commercial research due to lack of certainty and clarity over access and benefit sharing (ABS) requirements [7, 8] .
The synergies between these new technologies, and the changing landscape for biodiscovery, led many pharmaceutical companies to either cut back or disband their NP drug discovery programs and shift resources into the new paradigm. The situation worsened for NP extract screening as the speed of discovery became de rigor, although this later morphed into the "fail fast, fail cheap" mantra, as combinatorial libraries did not live up to the high expectations placed on them.
To maintain the forward momentum of projects performed in industry that utilized both pure compound library and NP extract screening, hits from pure compound libraries were often progressed to lead identification (hit-to-lead) in 6 months while it took 1-2 full-time employees (FTE) in this time frame to complete a reasonable number of bioassay-guided fractionations (e.g. 20) to arrive at the hit stage. The concomitant prosecution of both pure compound and extract screening highlighted several shortcomings of bioassay-guided fractionation when this modus operandi was simply translated to the new paradigm.
First, the screening group had to maintain cells or a quantity of protein for the NP group that delivered fewer and fewer fractions as the active component(s) were gradually purified. This is wasteful in terms of reagents being added to empty wells of microtiter plates and also in terms of time that screening staff could use to focus on a new assay. Second, structural elucidation of the actives was required following an often laborious isolation which could add to the frustration, particularly if the molecule violated most, if not all, lead-and drug-like physicochemical properties, or contained a substructure that was a medicinal chemistry "dead end". Third, if project reviews are carried out after 6 months, a not unreasonable period following initial screening then, more often than not, the same amount of data is not available for all isolations. Fourth, acquisition of secondary and counter screening data during hit identification, and early pharmacokinetic data for the hit-to-lead phase, potentially means that recollection of the original biota (microbial biota can be re-cultured) may be necessary so that the active component could be reisolated in larger quantities unless the molecule was synthetically tractable (and medicinal chemistry resources were available to attempt a synthesis).
As a result, NP drug discovery was increasingly marginalized and viewed as a last resort by project teams; only to be considered when screening the compound library did not yield any leads. Put simply, classical bioassay-guided fractionation so engrained in NP drug discovery was not competitive with the HTS timelines of pure compound libraries. Consequently, the quest for NP drug discovery over the past 20 years has been increasingly taken up by smaller niche companies offering a point of difference and the "true believers" from publicly funded research organisations, like the National Cancer Institute (U.S.A.), and various academic groups.
Yet, despite this somewhat melancholy backdrop, a recent review by Newman and Cragg has shown that NPs and their derivatives continue to make a significant contribution to the pharmaceutical industry [6] . Thus, from 1981-1987, NPs contributed substantially to the total number and percentage of all new drug approvals per annum.
After this, though, the number of drug approvals based on NPs and their semi-synthetic analogues began to drift downwards. To some extent, however, NPs are a microcosm of the pharmaceutical industry and the decreasing number of approvals each year is merely reflecting a general trend. Fortunately, the value of NPs is captured when analyzed as a percentage of all new drug approvals (notwithstanding the fact this metric resembles the fluctuations in the stock market). Hence, after a somewhat steady period between 1981-1986, a definite decline is observed from 1987-1991 where the percentage of new approvals drops to 20%. This is followed by a short rally over the next 3 years where the average jumps to 40% before a crash occurs in 1995 (29%) which turns into a definite bear market that reaches a nadir of 12.2% in 1997. A bullish, though somewhat erratic, run has since played out reaching a peak in 2010 where NPs and their derivatives accounted for 50% of all new drug approvals. Clearly, NPs are still furnishing leads to the pharmaceutical industry, albeit in lower total numbers than pre-1987. The challenge, as we see it, is to better integrate NPs into contemporary drug discovery so that both the total number and percentage contributions can increase.
Guiding principles for natural product drug discovery
To achieve this goal, we believe that there are two broad principles that together can underpin the discovery of NP drugs. Further development/refinement of these principles over time will not only deliver better leads for the pharmaceutical industry but will also make the screening of NP libraries more competitive and truly complementary to pure compound libraries.
Perhaps the easiest of these guiding principles to implement is to simply learn from the mistakes that initially plagued the combinatorial chemistry paradigm and develop NP workstreams that: 1) address physicochemical profiling prior to screening and; 2) make better use of technology to constantly shorten discovery timelines.
It should be noted that the early period of the combinatorial chemistry paradigm was not without controversy [9] . The focus on quantity and speed unfortunately meant that combinatorial chemistry and HTS was oversold as a panacea for the dearth of NCEs. When NCEs did not emerge from the pipeline, the focus rightly shifted away from throughput and towards quality. The readjustment was driven, in part, by a better understanding of the types of molecules that should be screened and the end point that resulted in a drug [10,11].
Lipinski et al.'s seminal analysis revealed that many combinatorial libraries contained molecules that did not echo specific physicochemical properties common to 90% of orally active drugs that advanced to phase II clinical trials. This disconnect led the authors to summarize their findings via the now well-known "Rule of 5" (Ro5) [12] , so-called because the first four parameters are all multiples of five. In essence, the Ro5 is a set of guidelines that articulates the ranges of four key properties assumed to be a good indicator of oral absorption, i.e., MW < 500; calculated Log P (cLog P) < 5; number of H-bond donors (HBD) < 5; and number of H-bond acceptors (HBA) < 10. In this sense, the Ro5 does not define drug-like chemical space per se but is rather a predictor for oral bioavailability [13] The second guiding principle is somewhat more ethereal in the sense that its execution is not generally able to be carried out by those involved in the science, but rather by high level policy makers from national governments. However, given the Convention on Biological Diversity (CBD) has fundamentally changed biodiscovery, it is absolutely essential that anyone contemplating NP drug discovery stays abreast of any developments and remains cognisant of emerging national and international legislation that permits ABS of genetic resources.
Clearly, NP drug discovery would not be possible without access to the world's biodiversity of which greater than 80% of terrestrial biodiversity is estimated to be spread across a mere 17 countries [24] . The distribution of the world's genetic resources is important as, historically, biodiversity has been approximately inversely proportional to a country's wealth and scientific capacity to not only undertake biodiscovery, but also commercialize outcomes [25] . A dichotomous paradigm has ensued whereby the developing world became a supplier of biodiversity (and sometimes associated traditional knowledge) that the developed world translated into commercial outcomes [26] . By the late 1980s many of the governments of developing countries and nongovernment organizations effectively lobbied that the situation was inequitable [27-29].
Interestingly, the global shift from NPs to combinatorial chemistry as a source of molecular diversity for screening programs coincided with the advent of the term "biopiracy" during the 1980s.
The disconnect between the wealth of genetic resources in the majority of megadiverse countries and their ability to translate this into a commercial outcome was central to international negotiations that resulted in a new treaty -the CBD -which was opened for signature at the first Earth Summit in Rio de Janeiro in 1992, and entered into force in 1993. The CBD has three clear objectives: the conservation of biodiversity, the sustainable use of its components, and the equitable sharing of benefits arising from the use of genetic resources [101] . In this respect the CBD is much more than an environmental treaty to address the alarming rate of global biodiversity loss; it is a hybrid that also deals with trade, development, and intellectual property rights [30] .
How these two guiding principles have been addressed by research groups from academia and industry to improve the underlying process, and by international law makers in creating the opportunity in the first place, will be discussed in more detail in their respective sections below.
Guiding principle 1: Addressing physicochemical properties in natural product
screening and improving the speed that hits, leads and drugs are isolated. 
Screening of pure natural product libraries

Screening crude extract libraries
Compound diversity is greatest in crude extracts and, as a consequence, their screening addresses the issue of minor components that may not be isolated using the pure NP strategy. 
Screening prefractionated extract libraries
Numerous prefractionation strategies have been developed to address issues associated with the HTS of crude extracts in an effort to maintain and detect minor components, improve the quality of screening data and reduce timelines associated with downstream bioassay-guided fractionation. Approaches are broadly scoped with reports ranging from the preparation of 4-200 fractions per sample. Table 2 summarizes published strategies for the preparation of prefractionated HTS-ready libraries.
1 were subjected to an automated purification and fractionation process that was followed 35 by dereplication and structure elucidation of the active components. However, the datafrom Merlion and Wyeth (obtained from 11 and 9 HTS campaigns, respectively) plainly 37 showed that hit rates were higher when fractions were screened compared with crude 38 extracts and suggests that screening a prefractionated library would be more efficient. 39
Indeed, lipophilic false positives like hexylcinnamaldehyde (cLog P
libraries based on crude extracts will be compromised in some way by the presence of 46 interfering high Log P constituents. Intriguingly, the screening of hexane extracts 47 (which potentially exacerbates the issues associated with crude extracts containing 48 lipophilic material) was also reported [43] . In one particular example described by the 49 authors at length, a common diterpene found in sponges, i.e. spongia-13(16),14-dien-50 19-oic acid (cLog P = 6.2), was isolated. 51
The prefractionated approaches listed in Table 2 and that Log P is considered "Lord of the Rules"-all of which were developed in 58 response to issues that originally troubled HTS of combinatorial chemistry libraries -it 59
follows that construction of a NP screening library, not only devoid of NP PAINS, but 60 also compliant with established lead-and drug-like parameters, particularly Log P, willenrich extracts (and subsequent fractions) with compounds that have a much higher 62 probability of progressing from hits to leads. Clearly, front-loading the screening set 63 will obviate the necessity to "build-in" functionality that accomplishes a more lead-or 64 drug-like profile at later lead identification/optimization stages. 65
Having generally not known before isolation is attempted, we would contend that an important 95 goal of NP drug discovery is to afford new and novel leads. To our way of thinking, the 96 structure is of secondary importance to ensuring the components are well positioned in 97 lead-and drug-like chemical space in the context of screening extracts and 98 prefractionated libraries. As a consequence, compounds that are isolated downstream 99 from screening will intrinsically adhere to physicochemical profiles that will justify a 100 potentially arduous isolation. Second, if NP drug discovery is to ever compete with 101 timelines for the HTS of pure compounds, then the rate at which NPs are isolated 102 requires vast improvement. 103
104
Next generation prefractionated extract libraries filtered on Log P 105
The correlation between lipophilicity and retention time on a C 18 reversed phase 106 HPLC column has been exploited to develop an alternative method to determine Log P 107
[48]. We have also observed a relationship between lipophilicity, as measured by a 108 compound's cLog P, and retention time on a C 18 reversed phase HPLC column while 109 undertaking bioassay-guided fractionation projects. Indeed, our earlier biodiscovery 110 efforts employing bioassay-guided fractionation following screening of 140,000 crude 111 extracts (35,000 macro biota extracted with 2 solvents and screened in duplicate) were 112 marred by pursuing late eluting, highly bioactive components that were ultimately 113 found to be useless as NP leads. Once this was realized, and understood in terms of 114 lead-and drug-like physicochemical properties, the process was modified accordingly 115 whereby the crude extracts were re-injected onto a reversed phase C 18 HPLC column 116 and analyzed [49] .
Over time, we recognized that molecules isolated from later eluting fractions 118 consistently had both cLog P and Log P values > 5 and, as a result, these fractions were 119 excluded from further analysis. While the fractionation process was a step in the right 120 direction and helped steer isolation projects toward lead-and drug-like compounds that 121 addressed Log P, it did not facilitate timely identification of actives. Clearly, a method 122 that pre-filtered extracts on Log P and allowed some preliminary structural data to be 123 obtained was required. Such a process would obviate the need to analyze extracts post-124 screening and concomitantly hasten the identification of potential hit compounds. 125
The lessons learned from fractionating extracts after screening guided our efforts 126 toward developing a generic approach that could be applied to both major and minor 127 constituents within crude or semi-purified extracts. Our current methodology [42] relies 128 on initially preparing crude extracts that are subsequently passed through an SPE 129 cartridge containing Oasis ® HLB, which is a copolymer of divinylbenzene and N-130 vinylpyrolidone. During exhaustive testing of adsorbents, we found that this particular 131 matrix was superior in retaining high Log P components that, in the past, were present 132 in the screening set. The process effectively filters on Log P and allows the earlier 133 eluting components that may contain a highly desirable basic nitrogen atom to be 134 captured. This observation also suggests that screening sets derived from Diaion™ HP- focus was on isolating compounds with Log P < 5 and MW < 500. Molecular weight 174
was not as critical as activity for the YOPE project and, as a consequence, bioactives 175 with higher MWs were isolated (Table 3) . We have previously reported [42] that the 176 118 compounds from the malaria and HAT projects were enriched in lead-and drug-177 like profiles compared with the Dictionary of Natural Products [60] . In some cases, the 178 NP lead has progressed into lead identification and optimization projects. So far, 179 synthetic follow-up has been published for YOPE [61] . 180
Interestingly, there were two compounds from the malaria project and seven 181 compounds from HAT that were not complaint with Log P < 5. Although the total 182 number of non-compliant molecules was small, the result was nevertheless puzzling 183 considering the process employed Log P as the primary filter. However, a more 184 thoughtful analysis would suggest that the presence of trifluoroacetic acid (a strong 185 acid) employed to filter on Log P would lead to ionization of NPs containing basic 186 moieties which, in turn, can lead to misleading results as Log P calculations specifically 187 predict the partitioning of neutral (i.e. un-ionized) species between n-octanol and water. 188
As a consequence, we believe that the distribution coefficient (Log D) is a more 189 appropriate measure as it considers the distribution of both ionized and un-ionized 190 species at a given pH. Indeed, it has been proposed that Log D at pH 5.5 (Log D 5.5 ), 191 which is the pH of the small intestine where oral drug absorption occurs, is a better As with many NP screening programs, the structure of each constituent in an extract or 218 fraction is generally not known prior to screening. The process described here addresses 219 Log P and MW so that the components adhere to contemporary concepts of lead-and 220 drug-likeness. It cannot, however, predefine structures. In some cases, although isolated 221 compounds may exist in lead-and drug-like space, they would not be considered for 222 further development, e.g. 16-18 which are reminiscent of DNA intercalators. NP 223 screening must therefore also be able to deliver two or three lead series in the same way 224 screening of pure compound libraries does so that a project team has options to pursue 225 if one series is chemically unattractive. Whilst singletons are not immediately 226 discounted, they can be considered too "high risk" and de-prioritized. This is 227 understandable given the cost to progress a lead through the drug discovery pipeline 228 The Nagoya Protocol is a major step forward in that it provides agreed 342 principles to deliver legal certainty and transparency for the entire value-chain of 343 biodiscovery, from original providers of the genetic resources, through to all stages in 344 the ensuing research and development, and the commercialisation process. Importantly, 345 the protocol includes provisions for clear demonstration of compliance, such as 346 certificates of compliance, and the introduction of checkpoints to transparently monitor 347 compliance. This is an important point as the potential for legal provenance and 348 compliance with the Nagoya Protocol may become a criterion for patentability in the 349 future [82] . 
Future perspective 369
The efficient screening and identification of small molecule modulators of 370 biological systems using HTS and high-content screening (HCS) will be employed for 371 many years to come. It is therefore paramount that NP researchers deliver new and 372 innovative approaches that dovetail with automated screening in order for NP drug 373 discovery to increase its current efficiency in identifying new drugs leads for 374 downstream development. 375
Innovation in delivering lead molecules is the key message here as many of the 376 technical challenges relating to isolation and structural elucidation of bioactive NPs 377 have been addressed [88, 89] . Many NP PAINS, for instance, can be removed prior to 378 screening while prefractionation to afford a screen-friendly set is readily accomplished 379 by HPLC. Moreover, it is becoming increasingly commonplace that the structure of 380 many active component(s) in a fraction can be determined by LC-MS and NMR 381 spectroscopy. This not only allows new and novel molecules to be distinguished from 382 previously identified compounds but also facilitates prioritization and allocation of 383 resources to isolation projects. The isolation of a pure compound in milligram quantities 384 can be achieved in a matter of hours using mass-directed isolation. Subsequent 385 structural elucidation by NMR spectroscopy is likewise completed in the same time 386 frame by skilled NP chemists. The entire procedure of going from an active fraction to a 387 defined molecule can be a matter of days rather than months [90] . 388
Other improvements to NP drug discovery that borrow from efficiency gains first 389 
Executive summary 440
Setting the scene 441  Slightly over 1,100 small molecule NCEs were introduced to the clinic from 442
